Promising IGKV6-21 as Drug Target and Biomarker (G28906)

Target Name: IGKV6-21

NCBI ID: G28906

Other Name(s): IGKV621 | Immunoglobulin kappa variable 6-21 (non-functional) | immunoglobulin kappa variable 6-21 (non-functional) | A26

Promising IGKV6-21 as Drug Target and Biomarker

IGKV6-21 (IGKV621) is a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. IGKV6-21 is a type of gene that is found in many organisms, including humans. It is a non-coding RNA molecule that is known for its role in the immune response and inflammation.

Recent studies have shown that IGKV6-21 is involved in a wide range of biological processes, including cell signaling, DNA replication, and stress responses. It is also known to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key reasons for the interest in IGKV6-21 is its potential as a drug target. IGKV6-21 has been shown to interact with a wide range of molecules, including proteins, drugs, and other small molecules. This makes it an attractive target for researchers to explore new treatments for a variety of diseases.

One of the main advantages of IGKV6-21 as a drug target is its ease of use. Unlike many other drug targets, IGKV6-21 is easy to manipulate and can be used in a variety of different settings, including cell culture, animals, and humans. This makes it an attractive target for researchers to study the effects of drugs on IGKV6-21 and to identify new treatments for a variety of diseases.

IGKV6-21 is also a promising biomarker for a variety of diseases. Its expression has been shown to be affected by a wide range of factors, including drugs, stress, and disease. This makes IGKV6-21 an attractive target for biomarker research, as it can be used to identify new diagnostic tools and potential therapeutic targets for a variety of diseases.

In addition to its potential as a drug target and biomarker, IGKV6-21 is also of interest to researchers as a potential therapeutic target for a variety of diseases. Studies have shown that IGKV6-21 can interact with a wide range of molecules, including proteins, drugs, and other small molecules. This makes it an attractive target for researchers to study the effects of drugs on IGKV6-21 and to identify new treatments for a variety of diseases.

Overall, IGKV6-21 is a promising drug target and biomarker for a variety of diseases. Its ease of use and potential as a therapeutic target make it an attractive target for researchers to study the effects of drugs on IGKV6-21 and to identify new treatments for a variety of diseases. Further research is needed to fully understand the role of IGKV6-21 in biology and disease.

Protein Name: Immunoglobulin Kappa Variable 6-21 (non-functional)

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets